Dr Dafydd Alwyn Dart

2024

• Dart, D. A., Bevan, C. L., Uysal-Onganer, P. and Jiang, W. G. 2024. Analysis of androgen receptor expression and activity in the mouse brain. Scientific Reports 14(1), article number: 11115. (10.1038/s41598-024-61733-9)

2021

• Lanning, B., Webber, J., Uysal-Ongane, P., Jiang, W. G., Clayton, A. and Dart, D. A. 2021. Prostate cancer cell extracellular vesicles increase mineralisation of bone osteoblast precursor cells in an in vitro model. Biology 10(4), article number: 318. (10.3390/biology10040318)

2020

• Dart, D. A., Ashelford, K. and Jiang, W. G. 2020. AR mRNA Stability is increased with AR-antagonist resistance via 3' UTR variants. Endocrine Connections 9(1), pp. 9-19. (10.1530/EC-19-0340)

2019

• Kandil, S., Lee, K. Y., Davies, L., Rizzo, S. A., Dart, D. A. and Westwell, A. D. 2019. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry 167, pp. 49-60. (10.1016/j.ejmech.2019.01.054)
• Dart, D. 2019. Wnt-11 Expression promotes invasiveness and correlates with survival in human pancreatic ductal adeno carcinoma. Genes 10, pp. 921. (10.3390/genes10110921)

2018

• Dart, D. A., Kandil, S., Tommasini-Ghelfi, S., Almeida, G. S. d., Bevan, C. L., Jiang, W. G. and Westwell, A. D. 2018. Novel trifluoromethylated enobosarm analogues with potent antiandrogenic activity in vitro and tissue selectivity in vivo. Molecular Cancer Therapeutics 17(9), pp. 1846-1858. (10.1158/1535-7163.MCT-18-0037)
• Xie, M. et al. 2018. MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. Gastric Cancer 21(1), pp. 41-54. (10.1007/s10120-017-0721-x)

2017

• Dart, A. D., Uysal-Onganer, P. and Jiang, W. G. 2017. Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development. Oncogenesis 6(12), article number: 400. (10.1038/s41389-017-0007-5)
• Hu, T., Su, F., Jiang, W. G. and Dart, D. A. 2017. Overexpression of activin receptor-like kinase 7 in breast cancer cells is associated with decreased cell growth and adhesion.. Anticancer Research 37, pp. 3441-3451. (10.21873/anticanres.11712)
• Koushyar, S., Economides, G., Zaat, S., Jiang, W., Bevan, C. L. and Dart, A. 2017. The prohibitin-repressive interaction with E2F1, is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis 6, pp. e3333. (10.1038/oncsis.2017.32)

2016

• Owen, S. et al. 2016. Heat shock protein 27 is a potential indicator for response to YangZheng XiaoJi and chemotherapy agents in cancer cells. International Journal of Oncology 49, pp. 1839-1847. (10.3892/ijo.2016.3685)
• Xie, M., Dart, D. A., Owen, S., Wen, X., Ji, J. and Jiang, W. G. 2016. Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review). Oncology Reports 36(3), pp. 1191-1198. (10.3892/or.2016.4908)
• Dart, D. . A. and Bevan, C. L. 2016. In vivo imaging of nuclear receptor transcriptional activity. In: McEwan, I. J. ed. The Nuclear Receptor Superfamily., Vol. 1443. Methods in Molecular Biology New York, NY: Humana Press, pp. 203-217., (10.1007/978-1-4939-3724-0_13)

2015

• Koushyar, S., Jiang, W. G. and Dart, D. A. 2015. Unveiling the potential of prohibitin in cancer. Cancer Letters 369(2), pp. 316-322. (10.1016/j.canlet.2015.09.012)
• Owen, S., Martin, T. A., Dart, D. A., Ablin, R. J., Mason, M. D. and Jiang, W. G. 2015. The prostate Transglutaminase, TGase-4, is potentially linked to the junctional proteins at tight junctions of prostate tissues and prostate cancer cells [Abstract]. European Journal of Cancer 51(S3), pp. S481., article number: 2516. (10.1016/S0959-8049(15)30048-4)
• Owen, S., Dart, D. A., Cui, Y., Ablin, R., Mason, M. D. and Jiang, W. G. 2015. Potential interactions between Interleukin-20 and Transglutaminase 4 might affect prostate cancer cell function [Abstract]. European Journal of Cancer 51(S3), pp. S26-S27. (10.1016/S0959-8049(16)30088-0)
• Brooke, G. N. et al. 2015. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Molecular & Cellular Proteomics 14(5), pp. 1201-1216. (10.1074/mcp.M113.036764)

2014

• Fletcher, C. E., Dart, D. and Bevan, C. L. 2014. Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers. Endocrine-Related Cancer 21(5), pp. R409-R429. (10.1530/ERC-14-0208)

2013

• Dart, D. A., Waxman, J., Aboagye, E. O. and Bevan, C. L. 2013. Visualising androgen receptor activity in male and female mice. PLoS ONE 8(8), article number: e71694. (10.1371/journal.pone.0071694)
• Sita-Lumsden, A., Dart, D. A., Waxman, J. and Bevan, C. L. 2013. Circulating microRNAs as potential new biomarkers for prostate cancer. British Journal of Cancer 108(10), pp. 1925-1930. (10.1038/bjc.2013.192)
• Sita-Lumsden, A., Fletcher, C. E., Dart, D. A., Brooke, G. N., Waxman, J. and Bevan, C. L. 2013. Circulating nucleic acids as biomarkers of prostate cancer. Biomarkers in Medicine 7(6), pp. 867-877. (10.2217/bmm.13.104)

2012

• Dart, D. A., Brooke, G. N., Sita-Lumsden, A., Waxman, J. and Bevan, C. L. 2012. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene 31(43), pp. 4588-4598. (10.1038/onc.2011.591)
• Fletcher, C. E., Dart, D. A., Sita-Lumsden, A., Cheng, H., Rennie, P. S. and Bevan, C. L. 2012. Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer. Human Molecular Genetics 21(14), pp. 3112-3127. (10.1093/hmg/dds139)

2011

• Brooke, G. . N. et al. 2011. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Research 71(3), pp. 914-924. (10.1158/0008-5472.CAN-10-0874)

2010

• Dart, D. A., Fletcher, C. L. and Bevan, C. 2010. Inhibiting androgen receptor activity in prostate cancer by cofactor manipulation [Abstract]. EJC Supplements 8(5), pp. 32-33.

2009

• Dart, D. A., Spencer-Dene, B., Gamble, S. C., Waxman, J. and Bevan, C. L. 2009. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocrine-Related Cancer 16(4), pp. 1157-1169. (10.1677/ERC-09-0028)

2007

• Gamble, S. C. et al. 2007. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 26(12), pp. 1757-1768. (10.1038/sj.onc.1209967)

2006

• Powell, S. M. et al. 2006. Mechanisms of androgen receptor repression in prostate cancer. Biochemical Society Transactions 34(6), pp. 1124-1127. (10.1042/BST0341124)
• Adams, K. E., Medhurst, A. L., Dart, D. A. and Lakin, N. D. 2006. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene 25(28), pp. 3894-3904. (10.1038/sj.onc.1209426)

2004

• Dart, D. A., Adams, K. E., Akerman, I. and Lakin, N. D. 2004. Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase. Journal of Biological Chemistry 279(16), pp. 16433-16440. (10.1074/jbc.M314212200)
• Dart, D. A., Picksley, S. M., Cooper, P. A., Double, J. A. and Bibby, M. C. 2004. The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. International Journal of Oncology 24(1), pp. 115-125.

2001

• Picksley, S. M., Dart, D. A., Mansoor, M. and Loadman, P. 2001. Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein. Expert Opinion on Therapeutic Patents 11(12), pp. 1825-1835.